The Wegovy pill is semaglutide, and semaglutide has years of evidence behind it
A recent systematic review of GLP-1 agonist exposure found that animal studies showed risks such as fetal growth restriction and skeletal abnormalities, and due to limited human data, experts recommend stopping these medications in both pregnancy and during breastfeeding
After one year, patients using these medications experienced an average weight reduction of 15.3%, while those on other drugs lost around 8.3%
Maintenance sessions are often recommended to preserve long-term outcomes, especially for patients focused on cosmetic skin brightening
Recovery is not the absence of training
Despite what you may have read on Instagram, the mechanisms are genuinely different